COPDPhase 4NCT01794780
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
A Phase 4 study testing LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone in people with COPD, run by Novartis Pharmaceuticals at 2 sites in China.
Trial summary
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COPD
- What is being tested?
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,229 participants
- Where
- 2 sitesChina
- Study dates
- 5 Feb 2013to 25 May 2015
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Willing and able to provide informed consent
- Physician-diagnosis of COPD
- COPD patients requiring long-acting bronchodilator treatment
- Patients with spirometry available at baseline
Who cannot join
- Patients who have a diagnosis of asthma.
- Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to Visit 1.
- Current clinical diagnosis of other chronic respiratory illnesses
- Concurrent participation in a clinical trial or use of an investigational drug.
- Active malignancy or history of malignancy of any organ system
- Pregnant or nursing (lactating) women
- Women of child-bearing potential with no contraception Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
2 sites in 1 country.
China2 sites
Novartis Investigative Site
Beijing, 100730
Novartis Investigative Site
Zhengzhou
About this study
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set.
A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.
- Conditions
- COPD
- Being tested
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone, LABA/ICS based treatment: budesonide/formoterol, theophylline based treatment
- Keywords
- COPD, Chronic obstructive pulmonary disease (COPD),, Chronic obstructive lung disease (COLD),, Chronic obstructive airway disease (COAD),, Cronchitis,, Emphysema
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Emphysema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LABA based treatment: indacaterolDrug
LABA based treatment: indacaterol
LAMA based treatment: tiotropiumDrug
LAMA based treatment: tiotropium
LABA/ICS based treatment: salmeterol/fluticasoneDrug
LABA/ICS based treatment: salmeterol/fluticasone
LABA/ICS based treatment: budesonide/formoterolDrug
LABA/ICS based treatment: budesonide/formoterol
theophylline based treatmentDrug
theophylline based treatment
Other treatmentDrug
non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"
| Study group | Role | What they receive |
|---|---|---|
| Indacaterol | Experimental | LABA: Indacaterol, once a day, 150μg each time Receives: Drug: LABA based treatment: indacaterol |
| Tiotropium Bromide | Experimental | LAMA: Tiotropium Bromide, once a day, 18 μg Receives: Drug: LAMA based treatment: tiotropium |
| Salmeterol/Fluticasone | Experimental | LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg Receives: Drug: LABA/ICS based treatment: salmeterol/fluticasone |
| Budesonide/ formoterol | Experimental | Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg Receives: Drug: LABA/ICS based treatment: budesonide/formoterol |
| Indacaterol +Tiotropium | Experimental | Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg Receives: Drug: LABA based treatment: indacaterol; Drug: LAMA based treatment: tiotropium |
| LABA/ICS (Or budesonide/ formoterol)+ Tiotropium | Experimental | Salmeterol / fluticasone Or budesonide / formoterol Receives: Drug: LAMA based treatment: tiotropium; Drug: LABA/ICS based treatment: salmeterol/fluticasone; Drug: LABA/ICS based treatment: budesonide/formoterol |
| Oral theophylline | Experimental | Not described Receives: Drug: theophylline based treatment |
| Other treatment | Experimental | non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments" Receives: Drug: Other treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
Measured: Baseline,3 months
Secondary outcomes (5)
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
Measured: Baseline,12 months
COPD Exacerbation
Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.
Measured: Baseline,12 months
Change in Health Status Questionnaire MMRC
The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.
Measured: Baseline,3,6,9,12 months
Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score
The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.
Measured: Baseline,3,6,9,12 months
Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.
Measured: Baseline,3,6,9,12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2013 (estimated)
- Study start5 Feb 2013
- Primary completion25 May 2015
- Study completion25 May 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COPDStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,229 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01794780
- Sponsor's protocol ID
- CQAB149BCN01
- Status last verified
- Aug 2019
- First submitted
- 15 Feb 2013
- Last updated
- 26 Sep 2019
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Han J, Dai L, Zhong N, Young D. Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions. COPD. 2015 Apr;12(2):115-25. doi: 10.3109/15412555.2014.974741. Epub 2014 Dec 4.
PubMed 25474373
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- ClinicalTrials.gov ID
- NCT01794780
- Acronym / sponsor ID
- CQAB149BCN01
- Conditions
- COPD
- Keywords
- COPD, Chronic obstructive pulmonary disease (COPD),, Chronic obstructive lung disease (COLD),, Chronic obstructive airway disease (COAD),, Cronchitis,, Emphysema
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,229 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 5 Feb 2013 (actual)
- Primary completion
- 25 May 2015 (actual)
- Study completion
- 25 May 2015 (actual)
- First posted
- 20 Feb 2013 (estimated)
- Results
- Posted 26 Sep 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set.
A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Indacaterol | Experimental | Drug: LABA based treatment: indacaterolLABA: Indacaterol, once a day, 150μg each time |
| Tiotropium Bromide | Experimental | Drug: LAMA based treatment: tiotropiumLAMA: Tiotropium Bromide, once a day, 18 μg |
| Salmeterol/Fluticasone | Experimental | Drug: LABA/ICS based treatment: salmeterol/fluticasoneLABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg |
| Budesonide/ formoterol | Experimental | Drug: LABA/ICS based treatment: budesonide/formoterolBudesonide/formoterol, twice daily, two suction each time, 160/4.5 μg |
| Indacaterol +Tiotropium | Experimental | Drug: LABA based treatment: indacaterol, Drug: LAMA based treatment: tiotropiumIndacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg |
| LABA/ICS (Or budesonide/ formoterol)+ Tiotropium | Experimental | Drug: LAMA based treatment: tiotropium, Drug: LABA/ICS based treatment: salmeterol/fluticasone, Drug: LABA/ICS based treatment: budesonide/formoterolSalmeterol / fluticasone Or budesonide / formoterol |
| Oral theophylline | Experimental | Drug: theophylline based treatment |
| Other treatment | Experimental | Drug: Other treatmentnon-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments" |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Willing and able to provide informed consent
- Physician-diagnosis of COPD
- COPD patients requiring long-acting bronchodilator treatment
- Patients with spirometry available at baseline
Key exclusion criteria (7 listed)
- Patients who have a diagnosis of asthma.
- Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to Visit 1.
- Current clinical diagnosis of other chronic respiratory illnesses
- Concurrent participation in a clinical trial or use of an investigational drug.
- Active malignancy or history of malignancy of any organ system
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LABA based treatment: indacaterolLABA based treatment: indacaterol | Drug | Indacaterol, Indacaterol +Tiotropium |
| LAMA based treatment: tiotropiumLAMA based treatment: tiotropium | Drug | Indacaterol +Tiotropium, LABA/ICS (Or budesonide/ formoterol)+ Tiotropium, Tiotropium Bromide |
| LABA/ICS based treatment: salmeterol/fluticasoneLABA/ICS based treatment: salmeterol/fluticasone | Drug | LABA/ICS (Or budesonide/ formoterol)+ Tiotropium, Salmeterol/Fluticasone |
| LABA/ICS based treatment: budesonide/formoterolLABA/ICS based treatment: budesonide/formoterol | Drug | Budesonide/ formoterol, LABA/ICS (Or budesonide/ formoterol)+ Tiotropium |
| theophylline based treatmenttheophylline based treatment | Drug | Oral theophylline |
| Other treatmentnon-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments" | Drug | Other treatment |
Primary outcome
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Baseline,3 months
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.
5 secondary outcomes
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Baseline,12 months
COPD Exacerbation
Time frame: Baseline,12 months
Change in Health Status Questionnaire MMRC
Time frame: Baseline,3,6,9,12 months
Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score
Time frame: Baseline,3,6,9,12 months
Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score
Time frame: Baseline,3,6,9,12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25474373Han J, Dai L, Zhong N, Young D. Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions. COPD. 2015 Apr;12(2):115-25. doi: 10.3109/15412555.2014.974741. Epub 2014 Dec 4.
Related trials for COPD
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
Not yet recruiting
Impact of Multidisciplinary Care, Structured and Targeted on the COPD Patient's Clinical Pathway.
Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive
Not yet recruitingPhase 3
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruitingObservational study
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing LABA based treatment: indacaterol, LAMA based treatment: tiotropium and LABA/ICS based treatment: salmeterol/fluticasone in people with COPD, run by Novartis Pharmaceuticals at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) (time frame: Baseline,3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01794780, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2019.